Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression

Experimental Oncology

Volumn 35, Issue 4, 2013, Pages 295-302

  Semesiuk, N ^a   Zhylchuk, A ^b   Bezdenezhnykh, N ^a   Lykhova, A ^a   Vorontsova, A ^a   Zhylchuk, V ^b,c   Kudryavets, Yu ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Rivne Region Oncology Hospital   (Ukraine)

^c DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

Author keywords

Bone marrow; Breast cancer; Disseminated tumor cells; Interferon ; Interleukin 6; Macrophage colony stimulating factor; Transforming growth factor 1; Tumor necrosis factor ; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; COLONY STIMULATING FACTOR 1; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; BONE MARROW; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MIDDLE AGED; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL;

ADULT; AGED; BONE MARROW; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS;

EID: 84892741914     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Campos M, Prior C, Warleta F, et al. Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques. J Histochem Cytochem 2008; 56: 667-75.
2. Lianidou ES, Mavroudis D, Sotiropoulou G, et al. What's new on circulating tumor cells? A meeting report. Breast Cancer Res 2010; 12: 307-18.
3. Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 2009; 132: 237-45.
4. Soria G, Ofri-Sharak M, Haas I, et al. Inflammatory mediators in breast cancer: Coordinated expression of TNF-α and IL-1β with CCL2 and CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011; 11: 130-49.
5. Lukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewnetrzhej 2007; 117: 1-5.
6. Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011; 3: 177-89.
7. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med 2004; 229: 1-11.
8. Patsialou A, Wyckoff J, Wang Y, et al. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony stimulating factor-1 receptor. Cancer Res 2009; 69: 9498-506.
9. Perera M, Tsang CS, Distel RJ, et al. TGF-β1 interactome: metastasis and beyond. Cancer Genomics Proteomics 2010; 7: 217-30.
10. Serra R, Crowley MR. TGF-beta in mammary gland development and breast cancer. Breast Dis 2003;18: 61-73.
11. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer; tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000; 2: 125-32.
12. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharm Rev 2004; 56: 549-80.
13. Nor JE, Christensen J, Mooney DJ, et al. Vascular endothelial growth factor (VEGF)-mediatedangiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154: 375-84.
14. Mohamed Ali E, Sheta M, El Mohsen MA. Elevated serum and tissue VEGF associated with poor outcome in breast cancer patients. Alexandria J Med 2011; 47: 217-24.
15. Ferrero S. Serum and plasma vascular endothelial growth factor levels in testicular cancer patients. Ann Oncol 2004; 15: 989-90.
16. Gagne D, Page M, Robitaille G, et al. Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Human Reprod 2003; 18: 1674-80.
17. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37-42.
18. Berne GJ, McDowell G, Agarawal R, et al. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007; 27: 3481-8.
19. Bezdenezhnykh NO, Lukyanova NYu, Lykhova OO, et al. Markers of cell proliferation, differentiation and malignancy of non-small cell lung carcinoma in the long-term IFN exposition. Cytology 2008; 50: 795-6 (in Russian).
20. Taniguchi T. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002; 1: 111-6.
21. Shayna A. Perforin and interferon-gamma activities independently control tumor initiation, growth and metastasis. Blood 2001; 97: 192-7.
22. Kudryavets YuI, Bezdenezhnykh NO, Lykhova OO, et al. The role of interferon as a modifier of epithelial-mesenchymal transition in tumor cells. Exp Oncol 2011; 33: 178-81.
23. Lang BA, Silverman ED, Laxer RM, et al. Spontaneuos tumor necrosis factor production in Kawasaki disease. J Pediatrics 1989; 115: 939-43.
24. Gascan H. Response of murine IL3-sensitive cell lines to cytokines of human and murine origin. Lymphokine Res 1989; 8: 79-84.
25. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Vir 1981; 37: 755-8.
26. Ni J, Hollander D. Application of the MTT-assay to functional studies of mouse intestinal intraepithelial lymphocytes. J Clin Lab Anal 1996; 10: 42-52.
27. Skenan F, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Nat Cancer Inst 1990; 82: 1107-12.
28. Vega-Avila E, Pugsley KM. An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc West Pharmacol Soc 2011; 54: 10-4.
29. Li C-Y, Ziesmer SC, Lazcano-Villareal O. Use of azide and hydrogen peroxide as an inhibitor for endogenous peroxidase in the immunoperoxidase method. J Histochem Cytochem 1987; 35: 1457-60.
30. Gluzman DF, Sklyarenko LM, Nadhornaya VA, et al. Diagnostic immunocytochemistry of tumors. Kiev: Morion, 2003: 78-91 (in Russian).
31. Schindlbeck C, Kampik T, Janni W, et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res 2005; 7: 1174-85.
32. Gerber B, Krause A, Miller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 960-71.
33. Vincent-Salomon A, Bidard FC, Pierga JY. Bone marrow micrometatasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol 2008; 61: 570-6.
34. Kasimir-Bauer S, Hoffmann O, Wallwiener D, et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012; 14: R15.
35. Osinsky SP, Gluzman DF, Kleeff J. Molecular diagnostics of tumor: basic principles and practical application: Monography. Kiev: "DIA". 248 p. (in Russian).
36. Braun S, Vogl FD, Naume B. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
37. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocrine-Related Cancer 2006; 13: 1033-67.
38. Apellaniz-Ruiz M, Castano Z. Adapt or dye: tumor microenvironment, a powerful regulator of cancer progression. J PostDoc Res 2013; 1: 1-8.
39. Chantrain CF, Feron O, Marbaix E, et al. Bone marrow microenvironment and tumor progression. Cancer Microenv 2008; 1: 23-35.
40. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clinical Chem 2006; 52: 345-51.
41. Daskalaki A, Agelaki S, Perraki M, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009; 101: 589-97.
42. Benoy IH, Elst H, Philips M. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circu lating tumour cells in patients with breast cancer. Br J Cancer 2006; 94: 672-80.
43. Waterston A, Bower M. TNF and cancer: good and bad? Cancer Ther 2004; 2: 131-48.
44. van Horssen R, Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insight, antitumor effects and clinical utility. Oncologist 2006; 11: 397-408.
45. Kudryavets YuI. Interferon and tumor necrosis factor as modifiers of metastasis of malignant tumors. Abstr of Doctoral Thesis. Kyiv 1999: 36 (in Ukrainian).
46. Kudryavets YuI. Modifying effect of recombinant tumor necrosis factor in the metastatic potential of tumor cells. Exp Oncol 1990; 12: 47-50 (in Russian).
47. Geng Y, Chandrasekaran S, Hsu J-W, et al. Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PloS One 2013; 8: e54959.
48. Semesiuk NI, Zhylchuk AV, Bezdenezhnykh NO, et al. Tumor necrosis factor in peripheral blood and bone marrow of breast cancer patients as a marker of the tumor progression. Oncologiya 2012; 4: 293-7 (in Ukrainian).
49. Sullivan NJ. Interleukin-6 in the breast tumor micro-environment. In: Breast Cancer - Focusing Tumor Micro-environment, Stem cells and Metastasis. M Gunduz (ed.), 2011: 165-75.
50. Sullivan NJ, Sasser AK, Axe AE, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009; 28: 2940-7.
51. Aharinejad S, Thomas A, Singer C. Significance of serum colony-stimulating factor-1 as a breast cancer marker. J Clin Oncol 2009; 27: 15s (suppl; abstr 11071).
52. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-40.
53. Buijs TJ, Stayrook KR, Guise TA. TGF-β in the bone microenvironment: role in breast cancer metastasis. Cancer Microenv 2011; 4: 261-81.
54. Ganapathy V, Ge R, Grazioli A, et al. Targeting the transforming growth factor-β pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010; 9: 122-38.
55. Piras F, Salani F, Bossu P, et al. High serum level of transforming growth factor β1 are associated with increased cortical thickness in cingulate and right frontal areas in healthy subjects. J Neuroinfl 2012; 9: 42-7.
56. Todorovic-Racovic N, Ivanovic V, Demaj M, et al. Elevated plasma levels of TGFbeta1 in patients with locally advanced breast cancer related to other clinical stages. Arch Oncol 2003, 11: 131-3.
57. Zhylchuk V, Lisnyak I, Vorontsova A, et al. Inhibitory effect of interferon-alpha on the level of VEGF in the blood serum breast cancer patients with complex treatment. Oncologiya 2008; 10: 321-6 (in Russian).
58. Zhylchuk V, Vorontsova A, Klyuchevska O, et al. Prognostic value of the level of TGF-beta in the blood serum breast cancer patients with interferon treatment. Oncologiya 2007; 9: 337-41 (in Ukrainian).
59. Moore LD, Isayeva T, Siegal GP, et al. Silencing of transforming growth factor-B1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 2008; 14: 4961-70.
60. Kallergi G, Markomanolaki H, Giannoukaraki V. Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Research 2009; 11: R84.
61. Vorontsova A, Bezdenezhnykh N, Zhylchuk V, et al. Inhibition expression VEGF in tumor cells and its level in serum of oncology patients by interferon-alpha. Urologiya 2009; 3: 48-52 (in Ukrainian).
62. Kudryavets Yu, Bezdenezhnykh N, Lukyanova N, et al. Modyfying influence of prolonged action of interferon on phenotypic characteristics of human lung cancer cells in vitro. Exp Oncol 2008; 30: 283-8.